## 1. Is the NGS consistent with the diagnosis?
The retrieval bundle assumed the submitted disease context as MDS and did not return a disease-fork warning. The retrieved MDS corpus evidence is prognostic rather than diagnostic: it states that MDS is risk-stratified by IPSS-M using haematological parameters, cytogenetics and somatic mutations, with SF3B1 included as a favourable molecular feature modulated by co-mutation pattern [ipssm-overview]. On the retrieved evidence alone, there is no mutation-driven argument against the submitted diagnosis of MDS with low blasts.

## 2. Prognosis  (+ / − / 0)
(+ for SF3B1 in the retrieved MDS evidence.) IPSS-M is the relevant MDS prognostic framework in this bundle, but the tool must not compute or estimate an IPSS-M score because the retrieved card says the score needs inputs not collected here, including full cytogenetics, blast percentage, cytopenias and 31 gene states [ipssm-overview]. Within that framework, SF3B1 mutation is associated with favourable outcome in MDS, although the effect is modulated by co-mutation pattern [ipssm-sf3b1-favourable]. The retrieved DNMT3A prognostic CIViC items are AML-focused, so I have not used them to assign MDS prognosis.

## 3. Therapy
The bundle did not return a curated corpus card establishing a targeted MDS therapy for SF3B1 or DNMT3A. It did return live CIViC predictive evidence for SF3B1 K700E in leukemia models: SF3B1-K700E compromised homologous recombination repair and increased sensitivity to ionising radiation, etoposide and olaparib in isogenic K562 cells and xenografts [CIViC:EID10139]. This is level D CIViC evidence in leukemia, not a direct MDS treatment recommendation. The bundle also returned recruiting studies relevant to MDS/SF3B1, including luspatercept plus darbepoetin in MDS [NCT:NCT07096297] and the Ferroptosis Study in SF3B1-mutant MDS [NCT:NCT05924074].

## 4. MRD biomarker
The retrieval bundle did not return a validated MRD-marker card for SF3B1 or DNMT3A in this MDS case. Therefore I would not nominate a molecular MRD marker from the retrieved evidence. DNMT3A is present at 32% VAF, but the bundle did not provide an MRD source supporting its use as a trackable residual-disease marker in this setting.

## Not assessed
No submitted genes were listed as unassessed by the retriever: SF3B1 and DNMT3A were both covered by at least one retrieved source.
